DMK Pharmaceuticals Corporation (DMKPQ) Research

DMK Pharmaceuticals Corporation functions as a clinical-stage neuro-biotechnology company, focusing on the development and market introduction of therapeutic solutions across several medical fields, including allergies, opioid overdose, respiratory conditions, and inflammatory diseases. Its primary product candidate currently in clinical trials is DPI-125, designed for the treatment of opioid use disorder. The company's portfolio also encompasses SYMJEPI, an epinephrine injection used for the immediate management of severe allergic reactions (anaphylaxis) triggered by factors such as insect stings, foods, medications, or those that are idiopathic or exercise-induced. Additionally, they offer ZIMHI, a naloxone injection vital for reversing opioid overdoses. The organization, previously named Adamis Pharmaceuticals Corporation, officially rebranded to DMK Pharmaceuticals Corporation in September 2023. Headquartered in San Diego, California, DMK Pharmaceuticals Corporation, along with its associated entities, filed for voluntary Chapter 11 bankruptcy reorganization in the U.S. Bankruptcy Court for the District of Delaware on February 2, 2024.

Open DMK Pharmaceuticals Corporation (DMKPQ) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.